신장 신경 차단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global renal denervation market size is expected to reach USD 14307.96 Million in 2034 from USD 678.86 Million in 2025, growing at a CAGR of 40.31 during 2026-2034.The global renal denervation market is gaining momentum as a promising treatment option for resistant hypertension. This minimally invasive procedure targets overactive nerves in the renal arteries, helping to reduce blood pressure in patients who do not respond well to medication. Increasing prevalence of hypertension and cardiovascular diseases has significantly contributed to market growth.

Key drivers include advancements in catheter-based technologies and growing clinical evidence supporting the effectiveness of renal denervation procedures. Rising awareness among healthcare professionals and patients has also boosted adoption. Additionally, the increasing burden of lifestyle-related diseases, such as obesity and diabetes, has created a strong demand for alternative treatment solutions.

In the coming years, the market is expected to expand with ongoing clinical trials and technological innovations. Improved device designs and enhanced procedural safety will drive adoption rates. As healthcare systems focus on preventive care and minimally invasive treatments, renal denervation is likely to become an important component of hypertension management strategies worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Type

• Symplicity
• Enlightn
• Vessix
• Paradise
• Iberis
• Others

By Technology

• Radiofrequency
• Ultrasound
• Micro-Infusion

By End User

• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Boston Scientific Corporation, Cardiosonic Ltd, Johnson & Johnson, Medtronic plc, Ablative Solutions Inc., Terumo Corporation, Mercator MedSystems Inc., ReCor Medical Inc., Renal Dynamics Limited, Abbott Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RENAL DENERVATION MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Symplicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Enlightn Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vessix Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Paradise Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Iberis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RENAL DENERVATION MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Radiofrequency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Ultrasound Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Micro-Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RENAL DENERVATION MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RENAL DENERVATION MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Technology
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Technology
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Technology
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Technology
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Technology
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL RENAL DENERVATION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Boston Scientific Corporation
  • 9.2.2 Cardiosonic Ltd
  • 9.2.3 Johnson & Johnson
  • 9.2.4 Medtronic Plc
  • 9.2.5 Ablative Solutions Inc
  • 9.2.6 Terumo Corporation
  • 9.2.7 Mercator MedSystems Inc
  • 9.2.8 ReCor Medical Inc
  • 9.2.9 Renal Dynamics Limited
  • 9.2.10 Abbott Laboratories